Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Toxins (Basel) ; 7(8): 3359-71, 2015 Aug 24.
Artigo em Inglês | MEDLINE | ID: mdl-26305256

RESUMO

The cholesterol synthesis inhibitor Triparanol has been shown to trigger apoptosis in several malignancies. Similar to the apoptosis of nucleated cells, erythrocytes may enter eryptosis, the suicidal death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Triggers of eryptosis include oxidative stress which may activate erythrocytic Ca(2+) permeable unselective cation channels with subsequent Ca(2+) entry and increase of cytosolic Ca(2+) activity ([Ca(2+)]i). The present study explored whether and how Triparanol induces eryptosis. To this end, phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca(2+)]i from Fluo3-fluorescence, and ROS formation from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) dependent fluorescence. As a result, a 48 h exposure of human erythrocytes to Triparanol (20 µM) significantly increased DCFDA fluorescence and significantly increased Fluo3-fluorescence. Triparanol (15 µM) significantly increased the percentage of annexin-V-binding cells, and significantly decreased the forward scatter. The effect of Triparanol on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca(2+). In conclusion, Triparanol leads to eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane. Triparanol is at least in part effective by stimulating ROS formation and Ca(2+) entry.


Assuntos
Eritrócitos/efeitos dos fármacos , Hipolipemiantes/toxicidade , Triparanol/toxicidade , Cálcio/metabolismo , Morte Celular/efeitos dos fármacos , Tamanho Celular/efeitos dos fármacos , Células Cultivadas , Membrana Eritrocítica/metabolismo , Eritrócitos/metabolismo , Glutationa/metabolismo , Hemólise/efeitos dos fármacos , Humanos , Fosfatidilserinas/metabolismo , Espécies Reativas de Oxigênio/metabolismo
2.
J Lipid Res ; 43(8): 1192-200, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12177163

RESUMO

Triparanol, an inhibitor of desmosterol Delta24 reductase, produces a high rate of limb malformations in rat fetuses exposed at gestational day 10 (gd 10) to a single oral dose (150-200 mg/kg) given to the pregnant dam. AY9944, another efficient distal inhibitor of cholesterol biosynthesis that blocks dehydrocholesterol Delta7 reductase, produces a similar degree of cholesterol depletion but fewer malformations. Gas liquid chromatography-mass spectrometry (GC-MS) profiling of the sterols in the serum of the dams and in extracted embryos shows that in addition to desmosterol Delta24 reductase inhibition the conversion of Delta8 to Delta7 unsaturated sterols is also blocked by Triparanol. Therefore, the inhibitor induces the accumulation of desmosterol (Delta8 cholesten-3beta-ol, 8-dehydrocholesterol) and zymosterol (Delta8, Delta24 cholestadien-3beta-ol) in embryo tissues. The high concentration of the teratogenic drug assayed in the embryos at three successive gestational days (10-30 micro g/g) is thought to cause the blockade in both Delta24 reductase and Delta8-Delta7 isomerase, which results in the particular profile of aberrant sterols. Comparison of the animal model with human syndromes, including limb osseous and skeleton perturbations, suggests a combination of desmosterol and Delta8 unsaturated sterols as being involved in the deleterious influence on limb bone formation.


Assuntos
Colesterol/biossíntese , Inibidores Enzimáticos/toxicidade , Deformidades Congênitas dos Membros/induzido quimicamente , Teratogênicos/toxicidade , Triparanol/toxicidade , Animais , Desmosterol/sangue , Desmosterol/metabolismo , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Masculino , Oxirredutases/antagonistas & inibidores , Gravidez , Ratos , Ratos Wistar
3.
Am J Clin Nutr ; 71(5 Suppl): 1270S-9S, 2000 05.
Artigo em Inglês | MEDLINE | ID: mdl-10799401

RESUMO

We showed previously that 3 distal inhibitors of cholesterol synthesis are highly teratogenic in rats. AY 9944 and BM 15766 inhibit 7-dehydrocholesterol reductase, which catalyzes the last step of cholesterol synthesis, and triparanol inhibits Delta(24)-dehydrocholesterol reductase, which catalyzes the last step in another pathway. These molecules cause holoprosencephalic brain anomalies. Under certain experimental conditions, other anomalies (of the limbs and male genitalia) are also observed. Assays performed by gas chromatography-mass spectrometry (GC-MS) show hypocholesterolemia and an accumulation of precursors. These data indicate that this animal model can be considered a model of Smith-Lemli-Opitz syndrome. Smith-Lemli-Opitz syndrome is a recessive autosomal genetic disease characterized by malformations (microcephaly, corpus callosum agenesis, holoprosencephaly, and mental retardation), male pseudohermaphroditism, finger anomalies, and failure to thrive. The syndrome has been attributed to a deficit in 7-dehydrocholesterol reductase. As assayed by GC-MS, the sterol status of these patients indicates severe hypocholesterolemia and an accumulation of precursors: 7-dehydrocholesterol, 8-dehydrocholesterol, and oxidized derivatives. The presence of 7-dehydrocholesterol in the serum of patients is pathognomonic of the disease. The developmental gene Shh (sonic hedgehog) plays a key role in brain, limb, and genital development; it was shown recently that the Shh protein has to be covalently linked to cholesterol to be active. This is the first time that a posttranslational function has been attributed to cholesterol. There is an obvious relation between Shh dysfunction and the malformations observed in our experiments and in patients with Smith-Lemli-Opitz syndrome. However, the exact relation remains to be clarified. It is clear, however, that the role of cholesterol in embryonic development must be taken into account.


Assuntos
Anticolesterolemiantes/toxicidade , Colesterol/fisiologia , Desidrocolesteróis/antagonistas & inibidores , Desenvolvimento Embrionário e Fetal/efeitos dos fármacos , Feto/metabolismo , Síndrome de Smith-Lemli-Opitz/embriologia , Animais , Modelos Animais de Doenças , Piperazinas/toxicidade , Ratos , Síndrome de Smith-Lemli-Opitz/induzido quimicamente , Síndrome de Smith-Lemli-Opitz/metabolismo , Triparanol/toxicidade , Dicloridrato de trans-1,4-Bis(2-clorobenzaminometil)ciclo-hexano/toxicidade
4.
Fed Proc ; 44(7): 2323-7, 1985 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-2579857

RESUMO

Administration of various cationic amphiphilic drugs in utero results in induction of a phospholipid storage disorder in many tissues, particularly in lungs. In addition to the phospholipidosis in utero, drug exposure results in toxicity to the offspring; newborn rats die within 48 h of birth. Although drug-induced pulmonary pathological changes appear to be involved in the observed mortality, this relationship remains unclear. In contrast to mammals, administration of cationic amphiphilic drugs to the chick embryo seems not to induce phospholipid storage in the tissues examined. Treatment of newborn rats directly with these drugs also induces phospholipidosis in several tissues including lung and kidney; however, mortality does not occur. Concurrent administration of phenobarbital and chlorphentermine reduces or prevents amphiphilic drug-induced phospholipid storage in newborn rat lung and kidney. Modification of chlorphentermine actions by phenobarbital may be caused by alterations in amphiphilic drug excretion, metabolism, and catabolic phospholipase activity. Evidence thus indicates that regardless of age, animals appear susceptible to the effects of cationic amphiphilic drugs; however, species and tissues examined, as well as specific drug administration, play an important role in the observed qualitative and quantitative responses.


Assuntos
Animais Recém-Nascidos/metabolismo , Clorfentermina/toxicidade , Feto/efeitos dos fármacos , Fentermina/análogos & derivados , Animais , Dexametasona/farmacologia , Interações Medicamentosas , Feminino , Gentamicinas/toxicidade , Lipidoses/induzido quimicamente , Pulmão/efeitos dos fármacos , Fenobarbital/toxicidade , Fosfolipídeos/metabolismo , Piperazinas/toxicidade , Gravidez , Triparanol/toxicidade , Dicloridrato de trans-1,4-Bis(2-clorobenzaminometil)ciclo-hexano/toxicidade
5.
Fundam Appl Toxicol ; 4(1): 105-19, 1984 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-6692999

RESUMO

The susceptibility of the endocrine tissues to compound-induced lesions may be ranked in the following decreasing order of frequency: adrenal, testis, thyroid, ovary, pancreas, pituitary, and parathyroid. The first two are by far the most frequently affected. Pathologists unaccustomed to the evaluation of endocrine effects are often unaware of the number of compounds producing specific lesions in the adrenal. Compounds may produce changes in one of the following zones: fasciculata/reticularis, glomerulosa, or medulla. They are listed in this paper by affected zones. In the fasciculata/reticularis lesions are generally either degenerative or proliferative; in the glomerulosa they are necrotic or atrophic; in the medulla lesions are generally hypertrophic or proliferative.


Assuntos
Glândulas Suprarrenais/efeitos dos fármacos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Córtex Suprarrenal/irrigação sanguínea , Córtex Suprarrenal/efeitos dos fármacos , Doenças das Glândulas Suprarrenais/induzido quimicamente , Glândulas Suprarrenais/fisiologia , Medula Suprarrenal/efeitos dos fármacos , Animais , Cricetinae , Cães , Cobaias , Brometo de Hexadimetrina/toxicidade , Humanos , Infarto/induzido quimicamente , Lipidoses/induzido quimicamente , Metanol/toxicidade , Camundongos , Coelhos , Ratos , Regeneração , Reserpina/toxicidade , Estresse Fisiológico/fisiopatologia , Triparanol/toxicidade
6.
Digestion ; 21(3): 156-62, 1981.
Artigo em Inglês | MEDLINE | ID: mdl-6163677

RESUMO

An immunoprecipitation procedure is presented for the measurement of rat intestinal alkaline phosphatase (I-AP) in feces. Controls exhibit a logarithmic normal distribution of fecal I-AP. Single administration of an agent toxic for small intestinal mucosa like bleomycin or triparanol induces an increase of fecal I-AP on the 1st day and a marked reduction of I-AP activity on the following 3 days. After the 5th day, abnormal high fecal I-AP activities were observed during regeneration. In parallel, morphometry and measurements of I-AP activity in the homogenate of small intestinal mucosa were performed. Rat fecal I-AP excretion proved to be a simple, non-invasive, sensitive marker for toxic damage of the small intestinal mucosa.


Assuntos
Fosfatase Alcalina/metabolismo , Bleomicina/toxicidade , Fezes/enzimologia , Mucosa Intestinal/enzimologia , Isoenzimas/metabolismo , Triparanol/toxicidade , Animais , Feminino , Imunoensaio , Mucosa Intestinal/efeitos dos fármacos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/enzimologia , Ratos
7.
Teratology ; 19(1): 39-43, 1979 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-88082

RESUMO

Cholesterol synthesis inhibitors administered to rats caused more or less complete forms of the holoprosencephalic syndrome, consisting of severe abnormalities of the brain, sense organs and pituitary. The absence of the pituitary was also observed in fetuses without externally visible cephalic abnormalities. These observations suggest that the isolated absence of the pituitary is the lesser form of the holoprosencephalic syndrome. This interpretation is also valid for cases of isolated absence of the pituitary observed in humans.


Assuntos
Anormalidades Induzidas por Medicamentos/etiologia , Cicloexanos/toxicidade , Hipófise/anormalidades , Triparanol/toxicidade , Dicloridrato de trans-1,4-Bis(2-clorobenzaminometil)ciclo-hexano/toxicidade , Anormalidades Induzidas por Medicamentos/patologia , Animais , Encéfalo/anormalidades , Feminino , Humanos , Gravidez , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...